INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,429 as of Tuesday, March 19, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,094 issues advancing vs. 1,811 declining with 142 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 2.0%, Alexion Pharmaceuticals ( ALXN), down 1.4%, Gilead ( GILD), down 1.3%, Celgene Corporation ( CELG), down 0.8% and Teva Pharmaceutical Industries ( TEVA), down 0.6%. Top gainers within the sector include HCA Holdings ( HCA), up 1.6%, Novartis ( NVS), up 1.2% and Shire ( SHPG), up 1.1%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector lower today:

4. Incyte ( INCY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Incyte is down $1.43 (-6.0%) to $22.36 on heavy volume Thus far, 1.7 million shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $22.22-$24.00 after having opened the day at $23.84 as compared to the previous trading day's close of $23.79.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.3 billion and is part of the drugs industry. Shares are up 43.2% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full Incyte Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)